Vaccination seems to be the most effective way to controlC. perfringens diseases. However, the industrial production ofClostridial toxins is laborious. Therefore, the production of tox-ins in heterologous expression systems is a viable alternative. Efficiency of vaccines based on Clostridium recombinant toxins has been reported . It has been shown that recombinant betaand epsilon toxins expressed in E. coli induce appropriate immuneresponses in mice and ruminants. In the present study, an epsilon-beta fusion toxin was expressed as asoluble protein in E. coli and the recombinant cell lysate was used for immunization studies in mouse.
Potency of the toxin (as an antigen) induced 6 and 10 IU/ml of epsilon and beta anti-toxin in rabbit,respectively. These titers were higher than the minimum level required by the European Pharmacopoeiafor epsilon and beta toxins. Experimental challenge with the recombinant fusion toxoid revealed that itcould protect mice against C. perfringens epsilon and beta toxins. Toxicity of the fusion toxin was studiedby histopathological findings, which were the same as the native toxins.
This is the first report describing the expression of fusionepsilon-beta toxin in E. coli. Our findings suggest this fusion as acandidate for the development of vaccine against C. perfringens typeD and B.Dr. Reza Pilehchian Langroudi, PhD
Vaccine 2013 Jul 23;31(32):3295-9. Epub 2013 May 23.
Department of Anaerobic Bacterial Vaccine Research and Production, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Download full-text PDF